Diazoxide for Lowering Insulin Levels in Breast Cancer Patients

Diazoxide is a nondiuretic benzothiadiazine that produces hyperglycemia by lowering insulin levels through activation of ATP‐sensitive K1‐channels and stimulating insulin degradation in the lysosomal system. Its effect on cancer growth is discussed.

Detalles Bibliográficos
Autores principales: Fink, Michael K., Klement, Rainer J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388385/
https://www.ncbi.nlm.nih.gov/pubmed/28400489
http://dx.doi.org/10.1634/theoncologist.2016-0402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388385/
https://www.ncbi.nlm.nih.gov/pubmed/28400489
http://dx.doi.org/10.1634/theoncologist.2016-0402

Ejemplares similares